HCPCS Code J2175: Meperidine hydrochloride injection billing guide

Key takeaways

HCPCS Code J2175 covers injection of meperidine hydrochloride, sold as Demerol, billed per 100 mg administered.

Billing units equal the dose in mg divided by 100, so a 150 mg dose is 1.5 units.

Wastage from a single-use vial needs a second claim line carrying modifier JW.

Modifier JZ reports zero waste, and CMS has required it for dates of service since July 1, 2023.

Practice management software like Pabau tracks J-code units and modifier assignments, so fewer claims come back denied.

HCPCS Code J2175 is a billable Level II code for injection of meperidine hydrochloride, sold under the brand name Demerol. It is billed per 100 mg administered, so the units on the claim follow the dose in the clinical note.

This reference covers unit calculation, Medicare reimbursement, route and wastage modifiers, the NDC entry, ICD-10 pairings, and the documentation a payer expects. Meperidine is a Schedule II drug, so several of those rules are stricter than they are for an ordinary J-code.

What HCPCS Code J2175 covers

HCPCS Code J2175 is a Level II J-series code maintained by the Centers for Medicare and Medicaid Services (CMS). J-codes cover drugs given by injection or infusion that a patient cannot self-administer. That makes them a staple of physician office and hospital outpatient billing.

CMS publishes the full Level II code set and its annual update files through the HCPCS program. Use those release files to confirm J2175’s status and effective dates at each annual refresh. The same system also carries service codes such as G0152, which follow different payment rules.

Meperidine hydrochloride (Demerol): Clinical context

Meperidine hydrochloride is a synthetic opioid analgesic, sold as Demerol. The Drug Enforcement Administration classifies it as a Schedule II controlled substance.

Its use in outpatient and procedural settings has narrowed over recent decades, mainly because the normeperidine metabolite builds up with repeated dosing. It is still billable in specific acute-pain scenarios.

Practices running IV therapy workflows should capture the route, the dose in mg, and the clinical indication at the point of care. Recording those fields after the fact is what turns a clean encounter into a denied claim.

Schedule II administration also needs an audit trail, which is where prescription management software with controlled substance logging earns its place.

• Drug class: Opioid analgesic (narcotic)
• DEA schedule: Schedule II, meaning high potential for abuse alongside accepted medical use
• Primary clinical indications: Pre-operative sedation, post-operative pain, procedural pain control, labor pain management
• Route of administration: Intramuscular (IM), intravenous (IV), or subcutaneous (SC) injection
• Safety note: Not recommended for chronic or repeated dosing, because the normeperidine metabolite accumulates

Post-operative pain is a common indication, including after breast surgery billed under 19316. Whatever the setting, the note must name the indication that justifies an opioid analgesic.

How to calculate billing units for J2175

J2175 is billed per 100 mg of meperidine administered. The units on the claim equal the dose in mg divided by 100. Partial units are acceptable and should reflect the dose given, not a rounded figure.

The dose documented in the clinical record must match the units billed. A mismatch between the mg in the administration note and the units on the claim is a common audit trigger. Document the exact dose at administration and let the billing system convert it.

Medicare reimbursement and fee schedule

Medicare pays for J2175 under Part B using Average Sales Price (ASP) methodology. CMS recalculates ASP each quarter from manufacturer-reported sales data, then pays ASP plus a percentage add-on. For most physician-administered drugs that add-on is 6%.

Because rates move every quarter, pull the current figure from the CMS ASP pricing files rather than from a static reference page.

The CMS fee schedule lookup lets coders search J2175 by code and by Medicare Administrative Contractor (MAC) jurisdiction. Facility and non-facility rates can differ depending on where the drug is given.

• Payment basis: Average Sales Price plus the applicable percentage add-on
• Update frequency: Quarterly, in January, April, July, and October
• Setting matters: Rates differ between physician office, hospital outpatient, and ambulatory surgical center
• Part B coverage: Applies to physician-administered drugs, with 20% patient coinsurance after the deductible

Meperidine is a Schedule II controlled substance, so some MAC jurisdictions attach extra documentation conditions to coverage. Check your MAC’s Local Coverage Determinations (LCDs) in the Medicare Coverage Database before you submit.

How to bill J2175 step by step

Accurate J2175 billing follows the same workflow every time, from dose capture to claim submission. Skip a step and the claim either denies or surfaces later in a post-payment audit. Structured medical forms at the point of care handle most of it automatically.

1. Document the dose in mg at administration, including the amount drawn, the amount given, and any discarded remainder
2. Confirm the route of administration (IV, IM, or SC) and record it in the clinical note
3. Calculate billing units by dividing the dose administered in mg by 100
4. Select the companion CPT administration code that matches the route and the setting
5. Apply route-of-administration modifiers, JA or JB, where the payer requires them
6. Apply wastage modifiers: JW for discarded drug, JZ when nothing is discarded from a single-use vial
7. Enter the NDC for the meperidine product used, with its qualifier and quantity
8. Submit the supporting ICD-10 code that documents medical necessity

Required modifiers for J2175

CMS requires route-of-administration modifiers on Part B drug claims where they apply. For J2175, the two route modifiers you will use most are JA and JB.

Companion drug administration codes

J2175 pays for the drug only. A separate CPT administration code covers the act of injecting or infusing it. Bundling rules vary by payer, so check with your MAC before submitting.

Billing for drug wastage with the JW modifier

Meperidine usually comes in single-use vials. When part of the vial is given and the rest discarded, CMS wants the discarded amount on its own claim line with modifier JW.

Modifier JZ goes on the administered line when nothing is wasted. CMS has required JZ for dates of service on or after July 1, 2023. Reporting was voluntary from January 1, 2023, and CMS began rejecting non-compliant claims on October 1, 2023.

This two-modifier system applies to every J-code billed from a single-use vial. Practices choosing an EMR for injectable workflows should confirm the billing module supports separate lines for administered and wasted quantities. Modifier fields should populate from the administration record rather than from manual entry.

Here is how a claim looks when 50 mg is given from a 100 mg single-use vial.

When the full 100 mg vial is administered with nothing left over, bill one line for J2175 at 1.0 unit. Add modifier JZ, which has been mandatory since July 1, 2023, and skip the second line. The payer reads JZ as an explicit statement that nothing was discarded.

NDC to J2175 crosswalk

Medicare requires a National Drug Code (NDC) on Part B drug claims, J2175 included. The NDC identifies the product, the manufacturer, and the package size. Numbers differ by manufacturer, concentration, and container, so the NDC on the claim must match the vial used.

Good EHR integration links the dispensed product’s NDC to the J-code at the point of administration. That removes a manual entry step at claim time.

NDC numbers are product specific and change when a manufacturer updates a package configuration. Pull the NDC from the physical vial label, never from memory or a previous claim. The FDA NDC Directory lets you confirm a code against the labeler and package size on file.

ICD-10 codes that support medical necessity

Every J2175 claim needs an ICD-10-CM diagnosis code that establishes medical necessity for the meperidine. Payers deny claims where the diagnosis does not justify an injectable opioid analgesic. The code you pick has to match the documentation for that encounter.

The code has to reflect the pain condition documented, not a generic unspecified pain code. Claims that pair a non-specific pain code with an injectable Schedule II opioid draw review at a higher rate.

Choose the most specific code the note supports. Sports medicine practices treating acute traumatic injury usually land on G89.11, and the note has to name the injury behind it.

Payer coverage policies for J2175

Medicare Part B covers J2175 when medical necessity is documented and the claim meets the administering MAC’s LCD requirements. Coverage is not automatic. Meperidine’s narrowing clinical profile has prompted some MACs to publish coverage articles on injectable opioid analgesics specifically.

Commercial payers vary widely. Some require prior authorization for Schedule II injectables, especially outside a surgical episode. Meperidine records carry a billing audit dimension and a DEA compliance dimension at once. Your HIPAA compliance routine therefore shapes how you answer a payer audit request.

• Medicare Part B: Covered for physician-administered meperidine that meets medical necessity, priced from ASP, with the NDC required
• Medicaid: Coverage and prior authorization rules vary by state, so check the applicable state program
• Commercial payers: May require prior authorization, and a few exclude meperidine over its safety profile
• Hospital outpatient: J2175 may fall under an Ambulatory Payment Classification (APC), which pays differently from office rates

Who tracks these payer rules depends on the ownership model. The billing split between a group practice and a solo one is worth settling before you build the workflow.

Documentation that supports a J2175 claim

Coders rarely get the code itself wrong. Denials and audits usually trace back to a clinical note that does not support what the claim says. Every J2175 claim should rest on documentation covering the elements below.

• Dose in mg: The exact milligram amount drawn and administered, recorded by the administering clinician at the time
• Route of administration: IV, IM, or SC stated in the note, matching the administration CPT code and any route modifier
• Clinical indication: The pain condition or procedure that created the need for meperidine, supporting the ICD-10 code billed
• Ordering provider: The provider who ordered the meperidine, with their NPI if they did not administer it
• Wastage record: The amount discarded and the reason, written at the time of administration rather than later
• NDC from the dispensed product: The code taken from the vial label used, not from a stock record
• DEA compliance log: The Schedule II entry required by federal and state rules, kept separate but available for audit

Practices that model injectable encounters on their IV therapy intake form capture most of these fields during the clinical workflow. Digital intake forms that prompt for route, dose, and indication at the point of care remove most retroactive corrections.

Teams moving to paperless documentation tend to see J-code accuracy improve once the clinical record and the billing record draw on one data source.

How Pabau keeps J-code claims and clinical notes in step

In most practices the administration note lives in the clinical system and the claim is keyed somewhere else. A nurse writes 75 mg in the chart, and a biller later types 1.0 unit into the claim. Nobody notices until a payer does.

Practice management software like Pabau keeps both records in one place. The dose, route, wastage, and NDC captured at administration feed the claim directly, so the unit count follows the chart. Your billing team works from claims management screens fed by the same record, not a re-keyed copy.

The outcome is fewer corrections. Wastage lines get built from the wastage the clinician recorded, and the NDC comes from the product recorded at administration. Every Pabau subscription includes the whole platform, so billing accuracy is not something you buy as an upgrade.

Manage J-code billing from a single platform

Pabau keeps HCPCS units, modifiers, NDC entries, and wastage records in one workflow. Your billing team spends less time fixing claims and more time on patients.

Book a demo

Conclusion

J2175 is a small line on a claim that carries a lot of conditions. The code itself is easy. Proving the dose, the route, and the wastage is where the work sits.

If you change one thing after reading this, make it the point of capture. A note that records mg, route, indication, and discarded volume at the bedside removes almost every reason a J2175 claim comes back.

The trade-off worth remembering is that stricter capture costs a few seconds per administration and saves hours of rework each quarter. Book a demo to see how Pabau ties drug administration records to J-code billing in one workflow.

Continue your research

Billing another single-use vial drug with wastage? J9267 walks through unit calculation and JW reporting for paclitaxel injections.

Need the same workflow for another injectable? J0800 covers dosing units, coverage rules, and the documentation payers expect.

Collecting the patient share after Part B pays? Patient self-pay billing sets out how to quote, collect, and record balances without awkward conversations.

Billing the equipment as well as the drug? K0455 explains how infusion pump claims are documented and priced.

Training staff who handle controlled substance records? HIPAA training for employees outlines what the annual program has to cover and how to evidence it.

Frequently asked questions